|
| |
|
 |
| |
A leader in therapeutic monoclonal antibodies, ImClone Systems is committed to changing the world of cancer care by developing a
portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of tumor types.
Founded in 1984, ImClone has a rich culture of discovery and deep expertise in oncology. The company has utilized the many advances
made in the fields of molecular biology, oncology, genomics, and antibody engineering to build a novel pipeline of product
candidates designed to address specific genetic mechanisms involved in cancer growth and development. ImClone has several
investigational monoclonal antibodies in various stages of clinical development.
Following its acquisition by Eli Lilly and Company in 2008, ImClone Systems is accelerating its antibody pipeline development by
leveraging Lilly's global capabilities. ImClone's pipeline has several molecules in mid- to late-stage clinical development
targeting a variety of cancers.
ImClone's research and clinical development capabilities are augmented by its expertise in the scale-up and manufacturing of
biologics. The company's state-of-the-art FDA-approved manufacturing facilities in Branchburg, New Jersey, provide it with one of
the largest biologic manufacturing capacities in the world. ImClone's Bridgewater, New Jersey office, which also serves as its
headquarters, houses its clinical development and administration operations. The company's research headquarters are based in New
York City and it has international operations in Europe.
|
|
|
|
